X

Trial Profile

A phase III study to evaluate the safety and efficacy of Cyclobenzaprine (TNX-102 SL) in patients with post traumatic stress disorders

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclobenzaprine (Primary)
Indications Post-traumatic stress disorders
Focus Registrational; Therapeutic Use

Most Recent Events

22 Sep 2016 New trial record
29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, the company expects to initiate this study later in the year 2017.
29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study will support the planned New Drug Application (NDA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com